Equine Recurrent Uveitis: Diagnosis, Long-Term Monitoring, and Eye Preservation

Equine recurrent uveitis (ERU), historically termed moon blindness, is the most common cause of vision loss and blindness in horses worldwide. This article provides veterinarians with a structured approach to diagnosing ERU, differentiating it from other ocular diseases, implementing long-term medical therapy, and evaluating surgical options for eye preservation. The content is based on peer-reviewed literature and authoritative veterinary sources, with emphasis on practical clinical decision-making.

At a Glance

Clinical Presentation and Historical Context

Equine recurrent uveitis has been recognized for centuries, with early descriptions referring to it as moon blindness due to the perceived association with lunar cycles. The condition is characterized by repeated episodes of intraocular inflammation affecting the uveal tract, including the iris, ciliary body, and choroid. Each episode causes cumulative damage that can lead to cataracts, glaucoma, retinal detachment, and phthisis bulbi.

The historical term "moon blindness" appears in veterinary literature as early as 1881, when it was described as irido-choroiditis in horses (Irido-Choroiditis, Commonly Called Moon Blindness, in the Horse, The Journal of Comparative Medicine and Surgery, 1881, https://www.semanticscholar.org/paper/b0f7bf412374c99d5494bc3158af313693072e77). A special report from the Horse and Mule Association of America in 1937 documented observations from veterinarians across the United States, noting the seasonal and recurrent nature of the disease (Special Report from the Horse and Mule Association of America to Veterinarians who Reported in October November and December 1937 on Moon Blindness they had Observed in 1936 and 1937, 1937, https://www.semanticscholar.org/paper/c2cccc1cc49a6b5f8562d91722f95ee42f6e8d05). Modern understanding has refined the classification, etiology, and pathogenesis of ERU, distinguishing it from other causes of equine uveitis (Equine recurrent uveitis: classification, etiology, and pathogenesis, Compendium, 2011, https://pubmed.ncbi.nlm.nih.gov/21870351).

Veterinarians should recognize that ERU is an immune-mediated condition, often triggered by infectious agents such as Leptospira spp., but also associated with trauma, systemic infections, and idiopathic causes. The immune response involves both innate and adaptive mechanisms, with T-cell mediated autoimmunity playing a central role in perpetuating inflammation (Immunological Insights in Equine Recurrent Uveitis, Frontiers in Immunology, 2020, https://pubmed.ncbi.nlm.nih.gov/33488614). Comparative perspectives between human and equine uveitis have advanced understanding of the disease mechanisms (Equine recurrent uveitis: Human and equine perspectives, Veterinary Journal, 2015, https://pubmed.ncbi.nlm.nih.gov/26188862).

Diagnostic Approach

Comprehensive Ophthalmic Examination

A thorough ophthalmic examination is essential for diagnosing ERU and differentiating it from other ocular diseases. The examination should include:

• Visual assessment: Menace response, dazzle reflex, pupillary light reflexes (direct and consensual)
• Adnexal examination: Eyelids, conjunctiva, third eyelid for swelling, discharge, or masses
• Corneal evaluation: Fluorescein staining to rule out ulceration, assessment for edema, vascularization, or keratic precipitates
• Anterior chamber: Depth, presence of aqueous flare, cells, fibrin, or hypopyon
• Iris: Color changes, synechiae (anterior or posterior), atrophy, or nodules
• Lens: Cataract formation, lens luxation
• Vitreous: Opacities, hemorrhage, or inflammatory cells
• Fundus: Optic nerve head appearance, retinal detachment, chorioretinitis

Slit-lamp biomicroscopy is recommended for detailed anterior segment evaluation. Indirect ophthalmoscopy allows thorough fundic examination after pupillary dilation. The Merck Veterinary Manual provides additional guidance on equine ocular examination techniques (Merck Veterinary Manual, https://www.merckvetmanual.com/).

Diagnostic Testing

Aqueous Paracentesis

Aqueous paracentesis is a valuable diagnostic tool for confirming ERU and identifying infectious causes. The procedure involves collecting aqueous humor from the anterior chamber under sedation and topical anesthesia. Samples should be submitted for:

• Cytology: Evaluation for inflammatory cells, organisms
• Polymerase chain reaction (PCR): Detection of Leptospira DNA
• Culture: Bacterial or fungal isolation when indicated

The procedure carries risks including hemorrhage, lens damage, and infection, but when performed carefully by an experienced clinician, it provides critical diagnostic information.

Serology

Serologic testing for Leptospira antibodies is recommended, as Leptospira-associated uveitis is a common cause of ERU. Paired acute and convalescent sera (2-4 weeks apart) can demonstrate rising titers. However, serology alone cannot confirm ocular infection, as many horses have been exposed to Leptospira without developing uveitis.

Imaging

Ocular ultrasound is indicated when the posterior segment cannot be visualized due to cataract, miosis, or corneal opacity. Ultrasound can detect vitreous opacities, retinal detachment, lens luxation, and intraocular masses.

Differential Diagnoses

Several conditions can mimic ERU and must be ruled out:

• Corneal ulceration: Fluorescein staining differentiates
• Traumatic uveitis: History of blunt or penetrating injury
• Glaucoma: Elevated intraocular pressure, corneal striae, optic nerve cupping
• Intraocular neoplasia: Melanoma, squamous cell carcinoma, lymphoma
• Systemic infections: Equine influenza, equine herpesvirus, toxoplasmosis
• Immune-mediated keratitis: Primarily corneal involvement without significant anterior chamber inflammation

Medical Management

Acute Episode Management

The goals of acute ERU management are to control inflammation, relieve pain, prevent synechiae formation, and minimize permanent damage. Treatment should be initiated promptly based on clinical severity. The Compendium provides detailed treatment protocols for ERU (Equine recurrent uveitis: treatment, Compendium, 2011, https://pubmed.ncbi.nlm.nih.gov/21870352).

Topical Corticosteroids

Topical corticosteroids are the mainstay of anti-inflammatory therapy for ERU. Prednisolone acetate 1% or dexamethasone 0.1% are commonly used. Frequency depends on severity: every 2-6 hours initially, then tapered as inflammation resolves. Contraindications include corneal ulceration, which must be ruled out with fluorescein staining before initiation.

Topical Atropine

Atropine sulfate 1% is used to dilate the pupil, relieve ciliary spasm, and prevent posterior synechiae. Frequency is typically every 6-12 hours, but can be increased for severe miosis. Adverse effects include reduced tear production, colic in susceptible horses, and potential for ileus. Monitor for systemic effects, especially in ponies and miniature horses.

Systemic Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Systemic NSAIDs provide additional anti-inflammatory and analgesic effects. Flunixin meglumine or phenylbutazone are commonly used. Duration should be limited to 3-7 days for acute episodes to minimize gastrointestinal and renal adverse effects. Monitor for signs of colic, diarrhea, or decreased appetite.

Systemic Corticosteroids

For severe or refractory cases, systemic corticosteroids may be indicated. Prednisolone or dexamethasone can be used. Contraindications include laminitis risk, active infections, and corneal ulceration. Use with caution and only when topical therapy is insufficient.

Long-Term Maintenance Therapy

Chronic management aims to suppress subclinical inflammation and prevent recurrent episodes. Options include:

Topical Immunosuppressants

Cyclosporine A 0.2% or tacrolimus 0.03% can be used long-term to reduce inflammation without the adverse effects of corticosteroids. Frequency is typically every 12-24 hours. These agents are particularly useful for horses requiring prolonged therapy.

Systemic Immunosuppressants

For horses with frequent or severe recurrences, systemic immunosuppressants may be considered. Azathioprine or mycophenolate mofetil have been used, but evidence is limited. Regular monitoring of complete blood count and biochemistry is essential due to potential bone marrow suppression and hepatotoxicity.

Leptospira Vaccination

In regions where Leptospira-associated ERU is common, vaccination against Leptospira may reduce the risk of initial infection and subsequent uveitis. However, vaccination does not treat existing ERU and may exacerbate inflammation in some horses. Discuss risks and benefits with the owner.

Monitoring and Adjusting Therapy

Long-term monitoring is essential for ERU management. Recheck examinations should be performed every 3-6 months, or sooner if signs recur. Parameters to assess include:

• Visual function: Menace response, maze testing
• Intraocular pressure: Tonometry to detect glaucoma
• Anterior chamber inflammation: Slit-lamp examination for flare and cells
• Lens status: Cataract progression
• Fundus: Optic nerve atrophy, retinal detachment

Adjust therapy based on clinical findings. Taper medications during quiescent periods, but maintain a baseline level of immunosuppression in horses with frequent recurrences.

Surgical Interventions

Vitrectomy

Pars plana vitrectomy is a surgical option for horses with chronic, recurrent uveitis that is unresponsive to medical therapy. The procedure involves removing the vitreous humor, which contains inflammatory mediators and immune cells that perpetuate inflammation. Vitrectomy can reduce the frequency and severity of recurrences, and may preserve vision in selected cases. The Veterinary Clinics of North America Equine Practice provides comprehensive guidance on medical and surgical management of ERU (Medical and Surgical Management of Equine Recurrent Uveitis, Veterinary Clinics of North America Equine Practice, 2017, https://pubmed.ncbi.nlm.nih.gov/28985983).

Candidate selection is critical. Ideal candidates have:

• Active inflammation despite maximal medical therapy
• No significant cataract or glaucoma
• Good visual potential
• Owner commitment to postoperative care

The procedure is performed under general anesthesia by a veterinary ophthalmologist. Complications include hemorrhage, retinal detachment, cataract formation, and infection. Postoperative management includes topical and systemic anti-inflammatory medications for several weeks.

Suprachoroidal Cyclosporine Implants

Suprachoroidal cyclosporine implants provide sustained release of cyclosporine directly to the uveal tract, reducing inflammation without systemic adverse effects. The implant is placed surgically into the suprachoroidal space under general anesthesia. New methods of management for ERU have been described in the veterinary literature (Equine recurrent uveitis: new methods of management, Veterinary Clinics of North America Equine Practice, 2004, https://pubmed.ncbi.nlm.nih.gov/15271431).

Indications include:

• Horses with frequent recurrences despite medical therapy
• Cases where systemic immunosuppression is contraindicated
• Horses with unilateral disease

Implants can provide therapeutic cyclosporine levels for 12-24 months. Repeat implantation may be necessary. Complications include implant migration, extrusion, and infection.

Other Surgical Options

• Intravitreal injections: Corticosteroids or immunosuppressants can be injected directly into the vitreous cavity. This approach provides high local drug concentrations with minimal systemic effects. Repeat injections may be needed.
• Enucleation: Indicated for blind, painful eyes that are unresponsive to therapy. Prosthetic implants can be placed for cosmetic purposes.

Emerging Therapies

Research into novel treatment approaches continues. Gene therapy using intravitreal AAV-Equine-IL10 has been investigated in experimental models of autoimmune uveitis (Inhibition of experimental autoimmune uveitis by intravitreal AAV-Equine-IL10 gene therapy, PLOS ONE, 2022, https://doi.org/10.1371/journal.pone.0270972). Topical suppressor of cytokine signaling-1 (SOCS1) mimetic peptides have also been studied for mitigation of ERU (Open label safety and efficacy pilot to study mitigation of equine recurrent uveitis through topical suppressor of cytokine signaling-1 mimetic peptide, Scientific Reports, 2022, https://doi.org/10.1038/s41598-022-11338-x). These approaches remain investigational and are not yet standard clinical options.

Records and Measurements

Documentation Requirements

Accurate records are essential for managing ERU and communicating with owners and referring veterinarians. Document:

• Signalment: Age, breed, sex, color
• History: Onset, duration, frequency of episodes, prior treatments, response to therapy
• Ophthalmic examination findings: Visual status, intraocular pressure, anterior chamber inflammation grade (0-4), lens status, fundus findings
• Diagnostic test results: Aqueous paracentesis cytology and PCR, serology, imaging
• Treatment plan: Medications, doses, frequency, duration
• Monitoring schedule: Recheck intervals, parameters to assess
• Owner instructions: Signs to watch for, when to seek emergency care

Grading Systems

Standardized grading systems improve consistency and communication:

Outcome Measures

Track outcomes to assess treatment efficacy:

• Time to recurrence: Days, weeks, or months between episodes
• Severity of recurrences: Grade of inflammation, need for hospitalization
• Visual status: Maintained, decreased, or lost
• Quality of life: Owner assessment of comfort and function

Common Failure Patterns

Diagnostic Errors

• Misdiagnosis as corneal ulcer: Failure to perform fluorescein staining before starting corticosteroids
• Overlooking systemic disease: Missing Leptospira infection or other underlying causes
• Incomplete examination: Not performing dilated fundic examination, missing posterior segment pathology
• Failure to differentiate from glaucoma: Not measuring intraocular pressure

Treatment Failures

• Inadequate anti-inflammatory therapy: Starting with too low a dose or frequency
• Premature tapering: Reducing medications too quickly, leading to rebound inflammation
• Noncompliance: Owner not administering medications as prescribed
• Adverse effects: Corticosteroid-induced glaucoma, NSAID-induced gastrointestinal ulcers
• Failure to address underlying infection: Not treating Leptospira when indicated

Surgical Failures

• Poor candidate selection: Operating on eyes with advanced cataract or glaucoma
• Postoperative complications: Hemorrhage, infection, retinal detachment
• Recurrence after surgery: Incomplete removal of inflammatory mediators
• Implant failure: Migration, extrusion, or depletion of medication

Welfare and Safety Context

Animal Welfare Implications

ERU causes significant pain and discomfort during acute episodes. Chronic inflammation leads to progressive vision loss, which affects the horse's ability to navigate its environment, interact with other horses, and perform its intended use. Blind horses require special management to ensure safety and quality of life.

The World Organisation for Animal Health (WOAH) recognizes the importance of animal health and welfare in livestock and equine populations (Animal Health and Welfare, World Organisation for Animal Health, https://www.woah.org/en/what-we-do/animal-health-and-welfare). Veterinarians have a responsibility to provide timely and effective treatment to minimize suffering.

Owner Education

Owners should be educated about:

• Recognizing early signs of recurrence: Squinting, tearing, redness, photophobia
• Administering medications correctly: Eye drop technique, frequency, storage
• Monitoring for adverse effects: Colic, diarrhea, laminitis
• When to seek emergency care: Sudden vision loss, severe pain, corneal ulceration
• Long-term prognosis: Realistic expectations for vision preservation

The American Association of Equine Practitioners provides owner resources on equine health conditions (AAEP, https://aaep.org/horse-owners). The Merck Veterinary Manual also offers accessible information for horse owners (Merck Veterinary Manual, https://www.merckvetmanual.com/horse-owners).

Safety Considerations

• Corticosteroid use: Contraindicated in corneal ulceration, monitor for glaucoma
• NSAID use: Monitor for gastrointestinal and renal adverse effects, avoid concurrent use with other NSAIDs or corticosteroids
• Atropine use: Monitor for colic, especially in ponies and miniature horses
• Surgical procedures: Require general anesthesia, discuss risks with owner

Professional Escalation Criteria

When to Refer to a Veterinary Ophthalmologist

• Diagnostic uncertainty: Unable to differentiate ERU from other causes of uveitis
• Severe or refractory inflammation: Not responding to maximal medical therapy
• Surgical candidate: Considering vitrectomy, implants, or enucleation
• Complications: Glaucoma, cataract, retinal detachment
• Recurrent episodes: Frequent recurrences despite appropriate medical management

The American College of Veterinary Internal Medicine provides resources for specialist referral (ACVIM, https://www.acvim.org/).

When to Hospitalize

• Severe pain: Unable to eat, drink, or move normally
• Corneal ulceration: Requires intensive topical therapy and monitoring
• Systemic illness: Fever, lethargy, anorexia
• Surgical intervention: Preoperative preparation and postoperative monitoring

When to Consider Euthanasia

• Blind, painful eye unresponsive to therapy
• Poor quality of life despite medical and surgical management
• Owner unable to provide necessary care

Practical Decision Framework for Selecting and Adjusting ERU Therapy Based on Clinical Stage and Response

Managing equine recurrent uveitis requires a structured approach that accounts for the stage of disease, the horse's individual response to treatment, and the practical constraints of long-term care. Without a clear decision framework, veterinarians may default to escalating therapy without objective criteria, leading to unnecessary drug exposure, increased costs, and missed opportunities for surgical intervention. This section provides a stage-based decision framework, a record system for tracking treatment response, a troubleshooting method for common clinical scenarios, and a comparison of therapeutic approaches to guide clinical reasoning.

Stage-Based Decision Framework

The clinical course of ERU can be divided into four stages: acute flare, early quiescent, chronic active, and end-stage. Each stage requires a distinct therapeutic approach with specific goals, monitoring parameters, and escalation criteria.

Stage 1: Acute Flare

An acute flare is defined by the sudden onset of blepharospasm, epiphora, photophobia, miosis, aqueous flare, and hypotony. The primary goal is to suppress inflammation rapidly and prevent synechiae formation. Treatment should be initiated within hours of recognition.

Initial therapy:

• Topical prednisolone acetate 1% or dexamethasone 0.1% every 2 to 4 hours for the first 24 to 48 hours
• Topical atropine sulfate 1% every 6 to 12 hours until pupillary dilation is achieved
• Systemic flunixin meglumine 1.1 mg/kg intravenously or orally every 12 hours for 3 to 5 days

Monitoring at 48 hours:

• Recheck anterior chamber flare and cell grade using the standardized grading system
• Measure intraocular pressure to detect corticosteroid-induced glaucoma
• Assess pupillary dilation and comfort level

Decision point at 48 hours:

• If flare and cell grade have decreased by at least one grade and the horse is comfortable, continue topical corticosteroids every 4 to 6 hours and begin tapering systemic NSAIDs over 3 to 5 days
• If no improvement or worsening, consider adding systemic corticosteroids (prednisolone 1 to 2 mg/kg orally every 24 hours) and perform aqueous paracentesis for cytology and PCR if not already done
• If corneal ulceration is present, discontinue topical corticosteroids and switch to topical NSAIDs (flurbiprofen or diclofenac) and systemic NSAIDs, and treat the ulcer with appropriate antimicrobial therapy

Escalation criteria:

• No improvement after 72 hours of maximal medical therapy
• Development of glaucoma (intraocular pressure above 30 mmHg)
• Corneal ulceration that fails to heal within 7 days
• Signs of systemic illness such as fever or lethargy

Stage 2: Early Quiescent

Early quiescent stage begins when the acute flare has resolved, defined by minimal to no aqueous flare (grade 0 to 1), normal intraocular pressure, and a comfortable horse. The goal is to maintain remission and prevent recurrence while minimizing drug exposure.

Maintenance therapy:

• Topical corticosteroid taper: Reduce frequency by one dose every 3 to 5 days until the lowest effective frequency is reached, typically every 12 to 24 hours
• Topical atropine: Discontinue once the pupil is dilated and comfortable, but may be continued at a low frequency (every 24 to 48 hours) if posterior synechiae are present
• Systemic NSAIDs: Discontinue after 5 to 7 days unless the horse has a history of frequent recurrences

Monitoring schedule:

• Recheck examination at 2 weeks, then monthly for 3 months
• Document flare grade, cell grade, intraocular pressure, and lens status at each visit
• Owner should monitor for subtle signs of recurrence such as mild squinting or tearing

Decision point at 3 months:

• If no recurrence and flare grade remains 0 to 1, continue topical corticosteroid taper to every 24 to 48 hours
• If one mild recurrence occurred, maintain current frequency and consider adding a topical immunosuppressant such as cyclosporine 0.2% every 12 hours
• If two or more recurrences occurred, the horse has entered the chronic active stage and requires more aggressive therapy

Stage 3: Chronic Active

Chronic active ERU is characterized by frequent recurrences (more than two per year), persistent low-grade inflammation (flare grade 1 to 2 between episodes), or progressive ocular damage such as cataract formation or vitreous opacities. The goal is to suppress subclinical inflammation and reduce recurrence frequency.

Therapy options:

• Topical cyclosporine 0.2% or tacrolimus 0.03% every 12 hours as a steroid-sparing agent
• Topical corticosteroid every 24 hours in addition to cyclosporine for breakthrough inflammation
• Systemic immunosuppressants such as azathioprine 1 to 2 mg/kg orally every 24 hours or mycophenolate mofetil 10 to 20 mg/kg orally every 12 hours, with regular monitoring of complete blood count and biochemistry every 4 to 6 weeks

Monitoring schedule:

• Recheck examination every 4 to 6 weeks for the first 6 months
• Document flare grade, cell grade, intraocular pressure, lens status, and vitreous clarity
• Perform complete blood count and biochemistry every 4 to 6 weeks if on systemic immunosuppressants

Decision point at 6 months:

• If recurrence frequency has decreased to one or fewer per year and flare grade is 0 to 1 between episodes, continue current therapy and consider tapering systemic immunosuppressants after 12 months of stability
• If recurrence frequency remains two or more per year or progressive ocular damage is noted, refer to a veterinary ophthalmologist for surgical evaluation
• If adverse effects from systemic immunosuppressants occur (neutropenia, hepatotoxicity, gastrointestinal signs), discontinue and consider alternative therapy

Stage 4: End-Stage

End-stage ERU is defined by blindness, phthisis bulbi, or a painful eye unresponsive to medical therapy. The goal is to provide comfort and maintain quality of life.

Management options:

• Enucleation for a blind, painful eye
• Intrascleral prosthesis for cosmetic appearance after enucleation
• Medical management with topical corticosteroids and atropine as needed for comfort, though this is rarely sufficient for end-stage disease

Decision point:

• If the eye is blind and painful, enucleation is the most humane option
• If the eye is blind but comfortable, the horse can be managed as a blind horse with appropriate environmental modifications
• If the owner declines enucleation, discuss palliative care and quality-of-life assessment

Record System for Tracking Treatment Response

A standardized record system is essential for tracking treatment response over time and making objective decisions about therapy adjustments. The following template can be used for each recheck examination.

ERU Monitoring Record

Treatment Adjustment Log

Owner Observation Log

Owners should be provided with a simple log to record daily observations between veterinary visits. This log helps identify subtle changes that may indicate early recurrence.

A score of 2 or higher on any parameter should prompt the owner to contact the veterinarian for a recheck examination.

Troubleshooting Method for Common Clinical Scenarios

Scenario 1: Horse Not Responding to Topical Corticosteroids

Possible causes:

• Corneal ulceration preventing corticosteroid use
• Inadequate frequency of administration
• Poor owner compliance
• Severe inflammation requiring systemic therapy
• Underlying infection such as Leptospira

Troubleshooting steps:

1. Perform fluorescein staining to rule out corneal ulceration
2. Review owner's medication administration technique and frequency
3. Consider switching from prednisolone acetate to dexamethasone 0.1% for greater potency
4. Add systemic NSAIDs if not already prescribed
5. Perform aqueous paracentesis for cytology and PCR to identify infectious causes
6. If Leptospira is identified, consider systemic antimicrobial therapy such as doxycycline 10 mg/kg orally every 12 hours for 21 days

Scenario 2: Recurrence During Maintenance Therapy

Possible causes:

• Inadequate maintenance dose
• Noncompliance with medication schedule
• Concurrent illness or stress triggering inflammation
• Progression of underlying autoimmune disease

Troubleshooting steps:

1. Increase topical corticosteroid frequency to every 4 to 6 hours for 3 to 5 days
2. Add topical atropine if miosis is present
3. Consider adding a topical immunosuppressant such as cyclosporine
4. Evaluate for concurrent illness such as respiratory infection or dental disease
5. If recurrences are frequent (more than two per year), consider systemic immunosuppressants or surgical referral

Scenario 3: Elevated Intraocular Pressure During Corticosteroid Therapy

Possible causes:

• Corticosteroid-induced glaucoma
• Secondary glaucoma from chronic inflammation
• Pre-existing glaucoma

Troubleshooting steps:

1. Measure intraocular pressure with tonometry
2. If intraocular pressure is above 30 mmHg, reduce or discontinue topical corticosteroids
3. Switch to topical immunosuppressants such as cyclosporine or tacrolimus
4. Add topical glaucoma therapy such as dorzolamide 2% every 8 to 12 hours or timolol 0.5% every 12 hours
5. If intraocular pressure remains elevated, refer to a veterinary ophthalmologist for surgical evaluation

Scenario 4: Owner Reports Difficulty Administering Eye Drops

Possible causes:

• Horse is head-shy or resistant to handling
• Owner lacks proper technique
• Frequency of administration is impractical for the owner's schedule

Troubleshooting steps:

1. Demonstrate proper eye drop technique to the owner
2. Consider using a longer-acting formulation such as dexamethasone ointment instead of drops
3. Adjust frequency to a schedule that the owner can maintain, even if it means using a lower frequency with a more potent medication
4. For horses that are difficult to handle, consider systemic therapy or surgical options

Comparison of Therapeutic Approaches

Topical Corticosteroids versus Topical Immunosuppressants

Systemic NSAIDs versus Systemic Corticosteroids

Vitrectomy versus Suprachoroidal Cyclosporine Implant

Practical Implementation Steps

1. At initial diagnosis: Determine the stage of disease based on clinical examination and history. Initiate therapy according to the stage-based framework. Perform aqueous paracentesis and serology for Leptospira.

2. At each recheck examination: Use the ERU monitoring record to document findings. Compare current findings to previous visits to assess trend. Adjust therapy based on the decision points outlined for each stage.

3. When recurrence occurs: Use the troubleshooting method to identify the cause. Adjust therapy accordingly. If recurrences are frequent despite optimal medical therapy, discuss surgical options with the owner.

4. When considering surgery: Refer to a veterinary ophthalmologist for evaluation. Discuss the risks and benefits of each surgical option with the owner. Ensure the owner understands the postoperative care requirements.

5. For long-term management: Provide the owner with an observation log and instructions for when to contact the veterinarian. Schedule recheck examinations every 3 to 6 months for stable horses, and more frequently for horses with active disease.

Common Failure Patterns in Decision Making

• Delaying escalation: Waiting too long to add systemic therapy or refer for surgery when medical therapy is failing. This leads to cumulative ocular damage and reduced chances of vision preservation.

• Inadequate monitoring: Not performing regular recheck examinations or relying solely on owner reports. Subclinical inflammation can progress without obvious signs.

• Inconsistent grading: Using subjective terms such as "mild" or "moderate" instead of standardized grading systems. This makes it difficult to track changes over time.

• Ignoring owner compliance: Prescribing a treatment regimen that the owner cannot realistically maintain. This leads to poor outcomes and frustration for both the owner and veterinarian.

• Failing to address underlying infection: Not testing for Leptospira or other infectious causes, and not treating when indicated. This allows the underlying trigger to persist.

Welfare and Safety Context

The decision framework described here is designed to minimize suffering and preserve vision for as long as possible. Each stage has specific welfare considerations:

• Acute flare: Horses experience significant pain and photophobia. Prompt treatment is essential for welfare. Hospitalization may be necessary for severe cases.

• Early quiescent: Horses are comfortable but require ongoing medication. The goal is to maintain comfort while minimizing drug exposure.

• Chronic active: Horses may have intermittent discomfort and progressive vision loss. The goal is to reduce recurrence frequency and slow disease progression.

• End-stage: Blind horses can have good quality of life if they are comfortable and managed appropriately. However, a blind, painful eye is a welfare concern that requires intervention.

The World Organisation for Animal Health emphasizes the importance of timely and effective treatment to minimize suffering in animals (Animal Health and Welfare, World Organisation for Animal Health, https://www.woah.org/en/what-we-do/animal-health-and-welfare). Veterinarians should discuss welfare considerations with owners at each stage and make recommendations that prioritize the horse's comfort and quality of life.

Professional Escalation Criteria

Referral to a veterinary ophthalmologist should be considered when:

• The horse has frequent recurrences (more than two per year) despite optimal medical therapy
• Progressive ocular damage is documented, such as cataract formation, vitreous opacities, or retinal changes
• Glaucoma develops and is not controlled with medical therapy
• The horse is a candidate for surgical intervention such as vitrectomy or suprachoroidal cyclosporine implant
• Diagnostic uncertainty remains after initial testing
• The owner is considering enucleation and wants to discuss all options

The American College of Veterinary Internal Medicine provides resources for locating board-certified veterinary ophthalmologists (ACVIM, https://www.acvim.org/). Early referral is preferable to waiting until the eye has sustained irreversible damage.

Frequently Asked Questions

What is moon blindness in horses?

Moon blindness is the historical term for equine recurrent uveitis, a condition characterized by repeated episodes of intraocular inflammation. The name originated from the belief that episodes were linked to lunar cycles, though modern understanding recognizes it as an immune-mediated disease often triggered by infectious agents such as Leptospira. Historical references to moon blindness appear in veterinary literature from the 19th and early 20th centuries (Irido-Choroiditis, Commonly Called Moon Blindness, in the Horse, The Journal of Comparative Medicine and Surgery, 1881, https://www.semanticscholar.org/paper/b0f7bf412374c99d5494bc3158af313693072e77, Moon blindness (Equine Recurrent Uveitis) in the horse, Tijdschrift voor diergeneeskunde, 2004, https://www.semanticscholar.org/paper/82eb1c8e9337e83544d1adf8b46be83ee63561e4).

How is equine recurrent uveitis diagnosed?

Diagnosis is based on a complete ophthalmic examination including slit-lamp biomicroscopy and indirect ophthalmoscopy. Aqueous paracentesis for cytology and PCR, along with serology for Leptospira, can confirm the diagnosis and identify underlying causes. The classification and pathogenesis of ERU have been well described in the veterinary literature (Equine recurrent uveitis: classification, etiology, and pathogenesis, Compendium, 2011, https://pubmed.ncbi.nlm.nih.gov/21870351).

What are the treatment options for equine uveitis?

Treatment includes topical corticosteroids and atropine for acute episodes, systemic NSAIDs and corticosteroids for severe cases, and long-term immunosuppressants such as cyclosporine or tacrolimus. Surgical options include vitrectomy and suprachoroidal cyclosporine implants for refractory cases. The Compendium provides detailed treatment guidance (Equine recurrent uveitis: treatment, Compendium, 2011, https://pubmed.ncbi.nlm.nih.gov/21870352).

Can equine recurrent uveitis be cured?

There is no cure for ERU, but the condition can be managed with appropriate medical and surgical therapy. The goal is to control inflammation, prevent recurrences, and preserve vision. Long-term monitoring and owner education are essential for successful management. Immunological insights continue to inform treatment approaches (Immunological Insights in Equine Recurrent Uveitis, Frontiers in Immunology, 2020, https://pubmed.ncbi.nlm.nih.gov/33488614).

What is the prognosis for vision in horses with ERU?

Prognosis depends on early diagnosis, aggressive treatment, and control of inflammation. Horses with mild to moderate disease and good response to therapy may maintain vision for years. Those with severe or recurrent inflammation are at risk for cataract, glaucoma, and blindness. Medical and surgical management options can improve outcomes (Medical and Surgical Management of Equine Recurrent Uveitis, Veterinary Clinics of North America Equine Practice, 2017, https://pubmed.ncbi.nlm.nih.gov/28985983).

Are certain horse breeds more prone to ERU?

Yes, Appaloosas and Warmbloods are overrepresented in ERU cases. Appaloosas may have a genetic predisposition to immune-mediated uveitis. Other breeds including Thoroughbreds, Quarter Horses, and draft breeds can also be affected. Comparative studies between human and equine uveitis have explored breed-related factors (Equine recurrent uveitis: Human and equine perspectives, Veterinary Journal, 2015, https://pubmed.ncbi.nlm.nih.gov/26188862).

Can ERU be prevented?

Prevention focuses on reducing exposure to infectious triggers such as Leptospira. Vaccination against Leptospira may reduce the risk of initial infection. Prompt treatment of ocular trauma and systemic infections can also help prevent secondary uveitis. The World Organisation for Animal Health provides guidance on animal health management (Animal Health and Welfare, World Organisation for Animal Health, https://www.woah.org/en/what-we-do/animal-health-and-welfare).

When should I refer a horse with ERU to a specialist?

Referral to a veterinary ophthalmologist is recommended for diagnostic uncertainty, severe or refractory inflammation, surgical candidate evaluation, complications such as glaucoma or cataract, and frequent recurrences despite appropriate medical management. The ACVIM provides resources for specialist referral (ACVIM, https://www.acvim.org/).

Related Veterinary Guides

• California Medical
• Medical Certificate
• Diagnostic Medical Sonography Programs
• Veterinary Clinical Methods Procedures Surgical Interventions
• Clinical Biochemistry Urinalysis

References and Further Reading

• aaep.org
• www.merckvetmanual.com
• www.acvim.org
• Merck Veterinary Manual. Merck Veterinary Manual.
• Animal Health and Welfare. World Organisation for Animal Health.
• Immunological Insights in Equine Recurrent Uveitis.. Frontiers in immunology, 2020.
• Equine recurrent uveitis: Human and equine perspectives.. Veterinary journal (London, England : 1997), 2015.
• Equine recurrent uveitis: treatment.. Compendium (Yardley, PA), 2011.
• Equine recurrent uveitis: classification, etiology, and pathogenesis.. Compendium (Yardley, PA), 2011.
• Medical and Surgical Management of Equine Recurrent Uveitis.. The Veterinary clinics of North America. Equine practice, 2017.
• Equine recurrent uveitis: new methods of management.. The Veterinary clinics of North America. Equine practice, 2004.
• Irido-Choroiditis, Commonly Called Moon Blindness, in the Horse. The Journal of comparative medicine and surgery, 1881.
• Special Report from the Horse and Mule Association of America to Veterinarians who Reported in October November and December 1937 on Moon Blindness they had Observed in 1936 and 1937.. 1937.
• [Moon blindness (Equine Recurrent Uveitis) in the horse].. Tijdschrift voor diergeneeskunde, 2004.
• Moon blindness (Equine Recurrent Uveitis) in the horse. 2004.
• [Therapy of periodic ophthalmia (moon blindness) in the horse].. DTW. Deutsche tierarztliche Wochenschrift, 1975.
• Inhibition of experimental autoimmune uveitis by intravitreal AAV-Equine-IL10 gene therapy. Plos One, 2022.
• Equine recurrent uveitis: Treatment. Compendium Continuing Education for Veterinarians, 2011.
• Open label safety and efficacy pilot to study mitigation of equine recurrent uveitis through topical suppressor of cytokine signaling-1 mimetic peptide. Scientific Reports, 2022.

This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.